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Abstract: Background and aim: Preliminary evaluation of a wild green oat extract 
(WGOE) (Neuravena® ELFA®955, Frutarom, Switzerland) revealed an acute cognitive 
benefit of supplementation. This study investigated whether regular daily WGOE 
supplementation would result in sustained cognitive improvements. Method: A 12-week 
randomised, double-blind, placebo-controlled cross-over trial of WGOE supplementation 
(1500 mg/day) versus placebo was undertaken in 37 healthy adults aged 67 ± 0.8 years 
(mean ± SEM). Cognitive assessments included the Stroop colour-word test, letter 
cancellation, the rule-shift task, a computerised multi-tasking test battery and the  
trail-making task. All assessments were conducted in Week 12 and repeated in Week 24 
whilst subjects were fasted and at least 18 h after taking the last dose of supplement. 
Result: Chronic WGOE supplementation did not affect any measures of cognition. 
Conclusion: It appears that the cognitive benefit of acute WGOE supplementation does not 
persist with chronic treatment in older adults with normal cognition. It remains to be seen 
whether sustained effects of WGOE supplementation may be more evident in those with 
mild cognitive impairment.  
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1. Introduction 
Avena sativa L. (oats), in its various forms and extracts, has been traditionally used for its physical 
and psychological fortifying properties for centuries. The purported benefits include reduced risk of 
heart disease, mild anti-depressant effects, increased ability to cope with stress, reduced anxiety [1,2], 
anti-inflammatory properties [3] and relief of skin irritation [4]. Although some of these benefits await 
rigorous scientific substantiation, recent studies suggest that supplementation with an oat extract from 
green oats, Neuravena® (EFLA®955, Frutarom, Switzerland), can acutely improve mental function in 
humans [5,6]. A single oral dose of 2500 mg wild green oat extract (WGOE) in healthy humans 
significantly increase in theta electric brain activity in the left frontotemporal region during a 
concentration task, measured by computer aided topographical electroencephalometry, compared with 
a 1250 mg dose or a placebo. The significant increase in theta brain activity, an indicator of cognitive 
alertness, two hours post supplementation with WGOE [6], suggests the potential for a cognitive 
benefit. This potential cognitive benefit was recently supported in an acute intervention in our 
laboratory, where consumption of a single dose of WGOE (1600 mg) resulted in a reduction in the 
number of errors made in the Stroop colour-word test in older adults with below average cognition 
(DEMTECT score 9–16) [5], indicative of an improvement in attention and the ability to ignore distraction.  
The mechanism of effect of WGOE is currently unknown. In vitro bioassays of WGOE indicated 
inhibitory effects on monoamine oxidase B (MAO-B) and phosphodiesterase-4 (PDE4). Effects of the 
latter may have a vasodilator benefit in the central nervous system, promoting potential enhanced 
vasodilatation in the cerebral vessels, thus aiding cognitive function [7]. In addition, avenanthramides 
(bioactive compounds unique in oats) have been shown to enhance nitric oxide (NO) production in 
human aortic smooth muscle cells [8] and suppress inflammatory cytokines by inhibiting nuclear  
factor κB (NF-κB) activation [3]; both mechanisms may elicit vasodilation in the cerebral arteries.  
Mozolic et al. [9] recently showed that an enhanced ability to concentrate during a visual and auditory 
attention task was linked to an improvement in resting cerebral blood flow in healthy older adults. 
Indeed, cerebral blood flow is reduced in those with mild cognitive impairment [10]. However the 
association between enhanced cerebral perfusion and improved cognitive performance has yet to be 
established, especially in healthy older adults with normal cognition. 
Whilst interventions with some nutrients have demonstrated acute cognitive improvements with a 
single dose of supplement [11,12], these nutrients may not necessarily have persistent cognitive benefits 
with daily consumption over longer periods (i.e., 12 weeks) [13,14]. In terms of acute cognitive effects, it 
is not clear how long these effects persist for as the time between consuming the last supplement dose 
and the administration of cognitive tests in the literature is unclear. To assess a nutrient’s potential for 
improving human cognition over the longer-term; it is preferable for its effects to result from persistent, 
rather than transient, physiological changes. Therefore in this study, we aimed to expand on our previous 
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work with acute WGOE supplementation [5] to determine if daily consumption of a WGOE would 
result in sustained cognitive improvements in healthy older adults.  
2. Experimental Section  
2.1. Study Design and Participants 
A 12-week randomised, double-blind, placebo-controlled cross-over human dietary intervention 
trial with 1500 mg per day of WGOE or placebo was conducted at the Nutritional Physiology Research 
Centre, University of South Australia, Adelaide, in accordance with principles of Good Clinical 
Practice. The study was approved by the University of South Australia Human Research Ethics Committee 
and registered with the Australia and New Zealand Clinical Trials Registry (ACTRN12610000012077). 
Healthy males and females aged over 60 years were recruited from the public and provided written, 
informed consent prior to screening.  
During an initial screening visit, participants underwent a series of physiological and cognitive 
assessments to determine their eligibility before formally enrolling into the trial. Participants were 
assigned a study ID in the order of their enrolment. Participants were excluded if they met any of the 
following conditions: were unable to read and write English; unable to distinguish the colours “red”, 
“green”, “blue” and “yellow” without difficulty; were taking cognitive enhancers, anti-cholinergic 
medication or mood altering medications; had a history of serious head injury, diagnosed and/or 
treated mental illness, alcoholism, stroke or neurological condition; had cardiovascular disease or renal 
disease or diabetes or gastrointestinal disease or dyslexia; smoked or used nicotine replacement 
therapy; had changed antihypertensive medication in the preceding three months or were likely to do 
so during the trial; consumed more than one serve of oats (including oat products) on average per day.  
Additional exclusion criteria determined at screening included suspected dementia [15] (DEMTECT 
score < 9), or resting supine blood pressure (BP) > 160/100 mmHg. During the intervention, participants 
were instructed to maintain their usual dietary habits and level of physical activity. Outcome 
assessments obtained during screening were for familiarization purposes; therefore only participant 
demographics are reported.  
2.2. Sample Size 
This study was powered based on the effect size (d = 0.62) for the Stroop colour-word test 
uncorrected error responses from our acute study with WGOE [5] in which a difference of 2.2 ± 3.5 
(mean ± SD) errors was observed between 1600 mg WGOE and placebo. Assuming a similar effect 
size for the present study, 23 participants (male and/or female) were needed to give 80% power for 
statistical significance at alpha level of 0.05. Due to the length of intervention, 42 participants were 
recruited to allow for dropouts.  
2.3. Supplements 
The WGOE (Neuravena® EFLA®955) is an extract of a variety of Avena sativa L., wild green oat 
herb. Extraction method has been previously described [6]. Potentially bioactive constituents of oat 
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herb include avenanthramides, saponins, phytoalexin and flavonoids such as vitexin and isovitexin 
(Frutarom Switzerland Ltd Bibliographic Dossier).  
The WGOE and placebo supplements used in this intervention were supplied by ASK Intercity  
Co. Ltd., Japan, as authorised by Frutarom Switzerland Ltd., in powder form and pressed into 315 mg 
capsules. Each capsule of WGOE contained 300 mg of active ingredient and 15 mg of calcium 
stearate. Placebo capsules contained microcrystalline cellulose (154.5 mg), lactose (154.5 mg), cacao 
brown (4 mg) and safflower colour (2 mg). These ingredients are not known to have any physiological 
or psychological effects. WGOE and placebo capsules were near identical in appearance and presented 
in opaque bottles.  
2.4. Intervention Protocol  
Cognitive assessments were conducted in Week 12 and repeated in the same order in Week 24 of 
the trial (Figure 1). To reduce the possible influence of foods and medications on cognitive outcomes, 
participants arrived at the research centre at least 4 h fasted (no food, medication, fluids except water) 
and at least 18 h after taking their last treatment doses. One investigator was responsible for 
performing all cognitive assessments in the order listed below. 
Figure 1. Outline of study design. During the screening visit (Week 0), participants 
underwent physiological and cognitive assessments including supine blood pressure (BP), 
DEMTECT and Stroop colour-word test to ensure their suitability for the study before they 
were randomized to a treatment arm. A complete battery of cognitive assessments was 
conducted in Week 12 before participants switched over to the alternate treatment and 
repeated the same assessment battery in Week 24.  
 
2.4.1. Stroop Colour-Word Test 
The Stroop colour-word test is a cognitive test that requires participants to firstly read the names of 
colours printed in incongruent coloured ink (trial 1), then name the colours in which they are printed 
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(trial 2) as quickly as possible without making errors. The test measures the individual’s ability  
to suppress task-irrelevant responses (i.e., the tendency to read the colour name rather than name the 
colour) and ability to maintain attention and concentration [16]. The Stroop interference score was 
calculated as the time taken to name colours (trial 2) divided by the time taken to read colour names 
(trial 1). A higher Stroop interference score reflects the degree of interference afforded by suppressing 
the habit of reading words in order to name colours; thus higher scores reflect poorer performance. 
Uncorrected errors during trial 2 would reflect failure of inhibition [16]. 
2.4.2. Letter Cancellation Task  
The Letter Cancellation test comprises a 32 × 45 matrix of random capital letters. Participants are 
required to search for the letters “F” and “L” and cross them out as quickly as possible. Higher 
performance (less time taken and fewer errors) reflected higher attention and ability to ignore 
distraction. Strong test-retest reliability has been reported (r = 0.93) and moderate to strong convergent 
validity with other cognitive assessments that measure attention and concentration [17]. 
2.4.3. Rule-Shift Task 
The rule shift task required the participants to change their responses when the rules of the task 
changed after habituating to the previous rule. The task utilises four sets of 26 images of playing cards 
presented on a computer screen and participants were asked to respond to the colour of the suit of the 
cards. For example, in the first trial, participants were instructed to respond “yes” if the suit of the card 
was red and “no” if black, followed by a second trial in which they responded “no” if red and “yes” if 
black. A higher score, reflected by shorter time taken to complete the task and fewer errors, reflects 
higher mental switching ability and to inhibit task-irrelevant responses [18].  
2.4.4. Computerised Multi-Tasking Test Battery 
In the multi-tasking computerized battery (Purple Research Solutions, UK) [19], participants were 
presented with four tasks simultaneously on a computer screen to which they were required to attend 
and respond quickly to each task equally for 5 min. In one task window, participants scan through a  
4 × 4 matrix of numbers and select the highest digit. Upon successful completion, a fresh matrix of 
numbers appears. Another task comprises of a red dot drifting outwards from the centre of a circle. 
Before it falls outside, the participant must press the “reset” button located at the bottom of task 
window. In another task window, six red bars will rise at different rates. As soon as one of the red bars 
reaches the top, a “warning sign” flashes and the participant must select the bars in numerical 
sequence. Once completed, the task restarts itself. The fourth task window consists of four colour 
blocks (red, blue, green and yellow) and a name of colour printed in incongruent coloured ink. The 
participants are required to click on the colour block that corresponds with the colour of the text, not 
the word. Points are awarded for successful completion of each task. Participants are negatively scored 
if mistakes are made and if they fail to attend of a task within a randomly assigned allocated time. 
These tasks therefore assessed divided attention, concentration and the ability to ignore task-irrelevant 
information. This cognitive assessment has been used previously in studies that measure the effects  
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of bioactive nutrients on cognitive performance and has the sensitivity to detect treatment  
differences [20,21]. A higher score reflects their ability to multi-task with speed and accuracy.  
The multi-tasking test is a computer-based cognitive assessment tool, which may have a practice 
effect and/or some older adults were unaccustomed to using a computer mouse. Therefore, participants 
were familiarized with the computerized multi-tasking test battery during the screening visit, thereby 
reducing the practice effect during the intervention.  
2.4.5. Trail-Making Task  
The Trail-Making test is comprised of two parts that require participants to first draw lines to  
join numbers in ascending order. In the second part, participants are instructed to alternate  
(in ascending sequence) with letters and to search for the numbers and letters from a random array  
(i.e., 1-A-2-B-3-C-4-D, etc.). As such the task assesses mental switching, the ability to ignore 
distraction and to inhibit task irrelevant information [22]. 
2.5. Statistical Analysis 
Statistical analyses were performed using IBM SPSS Version 18.0 (New York, United States). The 
primary outcome was the number of uncorrected errors made during the colour-naming task on the 
Stroop colour-word test on which the study was powered. The effect of treatment was determined by 
within-individual comparison of the values obtained at the end of each treatment period using a paired  
t-test. Secondary outcomes were other improvements in cognitive performance as measured by the 
Stroop colour-word test, letter cancellation, rule-shift, trail-making and computerized multi-tasking test 
battery. Each cognitive outcome measurement (Stroop colour-word test, Letter cancellation, Rule-shift, 
computerized multi-tasking test battery and Trail-Making) was examined individually and then also 
collectively in the form of a composite attention-concentration index, which was obtained by summing 
the Z-scores of all the cognitive assessment data. A sequential Bonferroni adjustment was made to 
allow for multiple comparisons. Allowing for the fact that several assessments of the cognitive test 
battery were interdependent, the critical P-value for the most significant outcome was reduced  
from <0.05 to <0.005 (i.e., <0.05/10). All data are presented as mean ± SEM, unless stated otherwise.  
3. Results  
3.1. Participant Characteristics 
Of the 42 participants who were enrolled, 37 completed the two assessment time points in the  
24-week intervention and were included in the data analysis. Three of the five who withdrew were 
taking WGOE supplement—one was hospitalized and treated for angina, one had a change of BP 
medication and one withdrew due to gastrointestinal discomfort. Two participants (one had newly 
diagnosed breast cancer and one had gastrointestinal discomfort) were taking the placebo at the time  
of withdrawal.  
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Table 1. Participant characteristics at time of screening (data expressed as mean ± SEM). 
Blood pressure values were determined at screening. 
Participant characteristics at enrolment 
Number of Participants (Males/Females) 37 (25/12) 
Age (years) 67 ± 0.8 
Height (m) 1.71 ± 0.02 
Mass (kg) 77.4 ± 2.1 
Body Mass Index (kg/m2) 26.4 ± 0.6 
DEMTECT Score 17.5 ± 0.2 
SBP (mmHg) 127 ± 2 
DBP (mmHg) 71 ± 1 
Table 1 shows the participant characteristics. Participants in this study were healthy, normotensive 
but slightly overweight. They were also of normal cognition with DEMTECT scores ranging between 
14 and 19 out of a maximum score of 19, with a median score of 18 (mild cognitive impairment 9 to 
12 points, suspected dementia <9 points) [15]. During the intervention, the concomitant medications and 
dietary supplement use by participants included cholesterol-lowering (19%), anti-hypertensives (16%), 
gout (5%), fish oil (35%), calcium (14%) and multi-vitamins (17%). Compliance with the intervention 
was greater than 99% for both intervention arms (99 ± 0.8% for treatment dose; 100 ± 0.6% for placebo). 
3.2. Cognitive Outcomes 
Table 2 shows the results of each component of the cognitive assessments. No significant differences 
were observed in any of the individual tests or in the overall attention-concentration index.  
Table 2. Cognitive assessments. Data are presented as mean ± SEM, N = 37. A higher 
score reflects poorer performance with the exception of multitasking where it reflects  
better performance. 
WGOE Placebo ΔWGOE − Placebo t P 
Stroop Colour Word 
Word time (s) 92.4 ± 2.9 94.1 ± 2.9 −1.8 ± 1.1 −1.53 0.13 
Colour time (s) 203.1 ± 8.9 198.7 ± 7.7 4.5 ± 2.8 1.82 0.08 
Word uncorrected errors 0.5 ± 0.3 0.7 ± 0.5 −0.1 ± 0.6 −0.23 0.82 
Colour uncorrected errors 2.2 ± 0.5 2.1 ± 0.4 0.1 ± 0.4 0.37 0.72 
Word corrected errors 0.2 ± 0.1 0.3 ± 0.1 −0.1 ± 0.1 −0.70 0.49 
Colour corrected errors 2.4 ± 0.4 2.3 ± 0.4 0.1 ± 0.4 0.14 0.89 
Interference score 2.2 ± 0.1 2.1 ± 0.1 0.1 ± 0.04 2.26 0.04 
Letter Cancellation 
Time (s) 392.4 ± 11.5 395.9 ± 12.1 −3.5 ± 9 −0.39 0.70 
Errors 13.1 ± 1.5 14.7 ± 1.8 −1.6 ± 1.3 −1.21 0.23 
Rule Shift 
Rule shift 1 time (s) 25.2 ± 0.7 25.6 ± 0.9 −0.4 ± 0.8 −0.49 0.63 
Rule shift 1 errors 0.1 ± 0.05 0.1 ± 0.05 0.0 ± 0.1 0.00 1.00 
Rule shift 2 time (s) 27.0 ± 1.0 26.6 ± 0.9 0.4 ± 1.0 0.42 0.68 
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Table 2. Cont. 
Rule shift 2 errors 1.2 ± 0.5 1.1 ± 0.4 0.1 ± 0.6 0.23 0.82 
Rule shift interference 1 1.1 ± 0.03 1.1 ± 0.03 0.02 ± 0.04 0.51 0.61 
Rule shift 3 time (s) 37.5 ± 1.6 36.2 ± 1.2 1.3 ± 1.4 0.92 0.37 
Rule shift 3 errors 1.6 ± 0.3 1.3 ± 0.3 0.3 ± 0.4 0.60 0.55 
Rule shift 4 time (s) 46.2 ± 2.2 46.5 ± 2.3 −0.3 ± 2.6 −0.13 0.90 
Rule shift 4 errors 5.8 ± 1 6.4 ± 1.2 −0.6 ± 1.4 −0.44 0.67 
Rule shift interference 2 1.2 ± 0.05 1.3 ± 0.1 −0.05 ± 0.1 −0.61 0.55 
Trail Making 
Condition 1 time (s) 42.5 ± 2.4 40.1 ± 2.1 2.4 ± 2.3 1.04 0.30 
Condition 1 errors 0.2 ± 0.1 0.1 ± 0.1 0.1 ± 0.1 1.14 0.26 
Condition 2 time (s) 91.9 ± 5.2 92.5 ± 8.1 −0.6 ± 5.9 −0.11 0.92 
Condition 2 errors 0.7 ± 0.1 0.8 ± 0.2 −0.1 ± 0.1 −0.40 0.69 
Interference 2.3 ± 0.1 2.4 ± 0.2 −0.1 ± 0.1 0.73 0.47 
Multitasking Score 616.1 ± 74.7 602.8 ± 64.2 13.2 ± 41.8 0.32 0.75 
Attention-concentration Index 3.0 × 10−5 1.5 × 10−4 −1.2 × 10−4 0.00 1.00 
4. Discussion  
This is the first study to investigate the effects of chronic WGOE supplementation (1500 mg per 
day for 12 weeks) on cognitive performance in older adults. Our WGOE dose of 1500 mg/day for  
12 weeks was well-tolerated by the study participants. We found no significant change in the primary 
outcome measure, i.e., the number of errors made in the colour-naming trial (trial 2) of the Stroop 
colour-word test. There were no significant effects on any other measures of cognitive performance or 
in the attention and concentration index following chronic WGOE supplementation in this healthy 
sample of older adults.  
In our recent acute WGOE supplementation study, there was a significant reduction in the number 
of errors made during the Stroop colour-word test following acute supplementation with 1600 mg of 
WGOE compared with placebo [5]. Importantly, in our previous study those participants suspected of 
having mild cognitive impairment (DEMTECT score between 9 and 12, n = 7) demonstrated the 
biggest improvement in cognitive function. The remaining 29 participants had DEMTECT scores 
between 12 and 16 out of the maximum 19. In contrast, participants in the present study comprised 
healthy older adults with “normal” cognitive function who may have been less likely to show 
significant improvements in cognition. Furthermore, the median DEMTECT score in our study 
participants was 18 out of the maximum 19, which may represent a sampling bias due to the 
recruitment nature of volunteering for such dietary intervention with an aim to improve cognitive 
performance through supplementation. As such, our cohort is likely to fall within the upper deciles of 
cognitive performance in their age-group, thus reducing the likelihood of detecting statistical and/or 
clinically significant improvements with chronic WGOE supplementation. Future work with WGOE 
should include a sample with a range of DEMTECT scores. Nonetheless, albeit a small sample size, 
daily consumption of blueberry juice had beneficial effects on memory in older adults with mild 
cognitive impairment [23]. Perhaps the cognitive enhancing benefit of a single dose of WGOE seen in 
the acute study [5] may be due to a direct, transient increase in theta brain wave activity during a 
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concentration task, as previously observed [6]. The sustained effect of WGOE on human brain wave 
activity has not been explored.  
Whilst there were no cognitive improvements following daily WGOE supplementation, we did not 
see any decline in cognitive performance after each arm of treatment. The rate of cognitive decline of 
older adults over time can be estimated by examining cognitive change in control groups. For example, 
a 12-month exercise intervention found significant within-individual decline in cognition in a control 
group of healthy older adults (65–74 years old), as measured using the Mini Mental State Examination 
(MMSE), even though the MMSE scores of the control group remained well-within the range of normal 
cognition after a year [24]. Considering the decline in cognitive performance with age [22] (and with  
time [24]), regular daily consumption of WGOE may be beneficial for attenuating age-related cognitive 
decline in healthy older adults. 
The cognitive assessment battery used in this study measured only one construct of cognition—attention 
and concentration. Whilst we recognised the anticipated age-related decline in memory [25], it would 
not have been feasible to include all domains of cognition in our study protocol as increasing the 
number of outcome variables would have increased the risk of Type 1 error within the sample size 
available. Our rationale for measuring this construct was based on our previous observation [5] of an 
acute benefit of WGOE on the Stroop colour-word test, a test designed to assess attention and 
concentration under duress [16]. Thus to increase the confidence of our cognitive tests, we selected a 
test battery focusing on assessing attention-concentration to increase the confidence of the findings. 
Cluster analysis examining the patterns of cognitive function across the lifespan revealed a discrepancy 
in cognitive performances between various cognitive domains among older adults (i.e., intact memory 
but reduced performance in attention) [22]. Given the heterogeneity in the decline of various cognitive 
domains among age-matched individuals we cannot rule out the possibility that other cognitive 
constructs such as memory, language, arithmetic and motor performance may be improved with 
chronic WGOE supplementation and therefore should be explored in future studies. 
In this study, cognitive tests were administered at least 18 h after participants consumed their last 
supplement dose. Thus, we were assessing whether chronic daily WGOE consumption would elicit a 
sustained cognitive benefit. Daily supplementation with 1500 mg of WGOE did not enhance cognitive 
performance in our study sample under our testing conditions. Preclinical evidence of WGOE 
indicated inhibitory effects on MAO-B, an enzyme that metabolises dopamine (a neurotransmitter in 
the central nervous system that regulates cognitive function [26]), and PDE4, which may have 
vasodilatory effects on cerebral arteries to enhance blood flow [7]. The short and long term effects of 
WGOE on dopamine levels and cerebral perfusion (together and independently) in humans and its 
relationship with human cognition is currently unknown. At this stage, we are unable to speculate if 
these are mechanisms by which WGOE may influence cognitive function. Nonetheless, it has been 
shown that avenanthramides (a polyphenol unique to oats) can be detected in the human circulation for 
up to 10 h following a serve of skim milk containing 1000 mg of avenanthramides [27]. In rats, 
avenanthramides accumulate in tissues for up to 12 h following oral ingestion [28]. The amount of 
avenanthramides in our 1500 mg dose of WGOE and its bioavailability and tissue accumulation 
following WGOE ingestion in humans are not known. Future research on the optimal quantity of 
avenanthramides in WGOE and the duration of supplementation for enhancing cognition is warranted. 
Additionally, the anti-inflammatory properties of avenanthramides in oats [3] may be helpful for those 
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with chronic conditions with underlying inflammation such as obesity or Metabolic Syndrome. 
Considering the relationship between inflammation and cognitive impairment [29], WGOE should also 
be evaluated in these populations. 
5. Conclusion  
In summary, 12 weeks of daily WGOE supplementation did not alter cognitive performance in  
our healthy and cognitively-normal older adults. The chronic effects of WGOE supplementation should 
be extended to those with, or at risk of, mild cognitive impairment and evaluated in other domains  
of cognition. 
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